Clinical trials
Humans clinical trials
Below are recruiting humans clinical trials, each written for real people, not researchers. We’re tracking 1,228 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06665100RecruitingPhase 2
Study of PUL-042 for RSV and Related Viruses in Immune-Compromised Patients
This trial tests an inhaled medicine (PUL-042) for people with blood cancers or who have had a stem cell transplant and now have a respiratory virus (parainfluenza, RSV, or human metapneumovirus). The goal is to see if the drug can help clear the virus and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT06657222RecruitingPhase 1/Phase 2
Study of TUB-030 for advanced solid tumors
This trial tests a new drug called TUB-030 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and effective.
New Haven, ConnecticutAges 18 years+ - NCT06658405RecruitingPhase 2
HPV vaccine after cervical lesion treatment
This trial tests whether an HPV vaccine (Gardasil 9) can help women over 45 who still have HPV after treatment for a high-grade cervical lesion. It compares vaccinated and unvaccinated patients to see if vaccination lowers the risk of the lesion coming back.
LilleAges 45 years+ - NCT06665074RecruitingPhase 2
Inflammation and aggression study
This trial tests how inflammation affects aggression by giving a small amount of a substance that briefly triggers your immune system. You may qualify if you have a diagnosis of Intermittent Explosive Disorder (IED), or if you are a healthy control without current anger issues.
Columbus, OhioAges 21–55 - NCT06636435RecruitingPhase 1
Study of CBA-1205 for advanced cancers including liver, melanoma, and pediatric cancer
This trial tests a new drug called CBA-1205 for people with advanced solid tumors, liver cancer, melanoma, or certain childhood cancers that have not responded to standard treatments. The drug targets a protein called DLK1 found on some cancer cells.
Kashiwa, ChibaAges 2 years+ - NCT06644755RecruitingPhase 1
First-in-human study of DS-2243a for advanced cancers
This trial tests a new drug called DS-2243a for people with advanced solid tumors that have stopped responding to standard treatments. It targets a specific protein found in some cancers, and you need to have a particular immune system marker for it to work.
Boston, MassachusettsAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
Springdale, ArkansasAges 18 years+ - NCT06639191RecruitingEarly Phase 1
Study of a new drug for cancers expressing CD44v6
This trial tests a new radioactive drug called [177Lu]Lu-AKIR001 for patients with certain advanced cancers (like thyroid, head and neck, lung, vulvar, or cervical cancer) that have a specific protein called CD44v6 on their surface. The goal is to see if this treatment can help when standard options have stopped working.
Stockholm, Stockholm CountyAges 18 years+ - NCT06636734RecruitingPhase 2
Lovastatin plus pembrolizumab for advanced head and neck cancer
This trial tests whether adding lovastatin (a cholesterol-lowering drug) to pembrolizumab (an immunotherapy) works better than pembrolizumab alone for head and neck cancer that has come back or spread. It's for people who haven't had immunotherapy before and aren't already on a statin.
Atlanta, GeorgiaAges 18 years+ - NCT06634355Enrolling by invitation
Testing how sugammadex crosses the placenta
This study uses donated placentas to see if sugammadex, a drug used to reverse anesthesia, can pass from mother to baby. The results may help guide safer anesthesia use in pregnant women.
Leuven, Vlaams-BrabantAges 18–45 - NCT06622005RecruitingPhase 1
Combination treatment for multiple myeloma that has returned
This trial tests a new drug (SX-682) added to a standard three-drug combination (carfilzomib, daratumumab, and dexamethasone) for people whose multiple myeloma has come back or stopped responding to previous treatment. The goal is to see if adding this drug helps control the cancer better.
Buffalo, New YorkAges 18 years+ - NCT06625034RecruitingPhase 3
Comparing two radiation planning methods for prostate cancer
This trial tests two ways to plan radiation treatment for prostate cancer: one using a computer program (RapidPlan) and the other using human experts. The goal is to see if the computer-assisted method works as well or better.
Scottsdale, ArizonaAges 18 years+ - NCT06628193Enrolling by invitation
Ultrasound effects on human memory study
This study uses low-intensity focused ultrasound to see how it affects memory. It may help researchers understand how to improve memory or treat conditions that affect it.
Roanoke, VirginiaAges 18–65 - NCT06627868Recruiting
NAD+ metabolism in human brown fat
This study explores how the body's natural substance NAD+ works in brown fat, a type of fat that burns calories. It may help researchers understand metabolism and find new ways to treat obesity.
TurkuAges 30–65 - NCT06622681Recruiting
Adolescent health and development research study
This study follows teenagers to understand their health, growth, and well-being during adolescence. It may help develop better support for young people.
Singapore, SingaporeAges 13–15 - NCT06617897RecruitingPhase 3
Fibrinogen concentrate to control bleeding in PMP surgery
This trial tests a medicine called fibrinogen concentrate (CSL511) to see if it helps control bleeding during a special surgery (cytoreductive surgery with HIPEC) for pseudomyxoma peritonei (PMP). The goal is to reduce the need for blood transfusions and improve safety.
BasingstokeAges 18 years+ - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
Los Angeles, CaliforniaAges 18 years+ - NCT06604663Enrolling by invitation
Using data to improve HIV care in Kenya
This trial is looking at how to improve HIV care by using data and interviews to help clinics make better decisions. It doesn't require you to do anything different—your regular clinic data will be used to see how well appointments are kept.
EldoretAges 18–100 - NCT06600568Recruiting
New treatment for T-cell cancers
This trial is testing a new approach to treat T-cell cancers (leukemia and lymphoma). It may be an option for adults with these cancers who are otherwise in reasonably good health.
NaplesAges 18 years+ - NCT06617195Recruiting
Why Muscle Building Slows Down in Older Adults
This study looks at why older adults have trouble building and keeping muscle. It tests how the body uses protein and exercise to help understand muscle loss with aging.
Rochester, MinnesotaAges 21–85 - NCT06591780Recruiting
Biofeedback to improve walking for diabetic nerve damage
This study tests a special biofeedback system to help people with diabetic nerve damage walk better. You'll use sensors during treadmill walking to see if real-time feedback can improve your stride and balance.
Pensacola, FloridaAges 45–90 - NCT06598397RecruitingPhase 4
Quit smoking help for people with HIV in NYC
This study is testing different ways to help people with HIV quit smoking. It combines medication, coaching, and text messages to find the most affordable and effective support.
New York, New YorkAges 18 years+ - NCT06599697RecruitingPhase 2
IVIG for anti-HMGCR muscle disease
This trial tests if IVIG (intravenous immunoglobulin, a donated blood product that helps the immune system) can improve muscle strength and reduce damage in people with anti-HMGCR immune-mediated necrotizing myopathy (a rare muscle disease where the immune system attacks muscle cells). It may help you if your muscle weakness is not too severe and you haven't tried IVIG before.
Birmingham, AlabamaAges 16 years+ - NCT06587113Recruiting
Study of attention and focus during visual search
This study explores how your brain focuses and ignores distractions while searching for things visually. It may help us understand attention processes in healthy adults.
Denver, ColoradoAges 18–65
Hear when a new Humans trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for humans?
- Yes. Clin2 currently lists 1,228 recruiting humans studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a humans trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a humans trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.